Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.

Pharmacogenomics - 1 Jan 2015

Mbatchi Litaty Céphanoée, Schmitt Antonin, Thomas Fabienne, Cazaubon Yoann, Robert Jacques, Lumbroso Serge, Brouillet Jean-Paul, Pourquier Philippe, Chatelut Etienne, Boyer Jean-Christophe, Evrard Alexandre

Abstract excerpt

AIM: The goal of our study was to assess the impact of patients' genetic background on their sensitivity to carboplatin/paclitaxel hematotoxicity. PATIENTS & METHODS: Parameters describing sensitivity to neutropenia and to thrombocytopenia of 201 patients were extracted from a previous pharmacokinetic/pharmacodynamics analysis, in order to assess their association with 52 candidates SNPs in 18 genes. RESULTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Carboplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Organic Anion Transporters, Sodium-Independent

Share to Paclitaxel

Share to Pregnane X Receptor

Share to Receptors, Steroid

Share to Solute Carrier Organic Anion Transporter Family Member 1B3

Share to Thrombocytopenia

Source

Identifiers

PMID: 26267044
DOI: 10.2217/pgs.15.84

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.PMID 26267044Read ↗

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.Semantic proximity Read ↗

GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.Semantic proximity Read ↗

Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.Semantic proximity Read ↗

ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients.Semantic proximity Read ↗

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.Semantic proximity Read ↗

Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.Semantic proximity Read ↗

ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers.Semantic proximity Read ↗

Predicting paclitaxel-induced neutropenia using the DMET platform.Semantic proximity Read ↗

Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients.Semantic proximity Read ↗

Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.Semantic proximity Read ↗

Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.Semantic proximity Read ↗

Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.